A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

NCT07478744 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Anxiety Disorder

Interventions

DRUG: SYT-510
DRUG: Placebo

Sponsor

Synendos Therapeutics AG